Author:
Lee Yi-Tzu,Chen Te-Li,Siu Leung-Kei,Chen Chien-Pei,Fung Chang-Phone
Abstract
ABSTRACTAnin vivodevelopment ofPantoea agglomeransmutants (isolates PA2 to PA4) with reduced ertapenem susceptibility from that of isolate PA1 was associated with an inadequate clinical response to ertapenem therapy. All four isolates harbored theblaACT-9AmpC β-lactamase gene. However, a loss-of-function mutation in theampDgene in PA2 to PA4, but not PA1, led to derepressed ACT-9. The reduced ertapenem susceptibility caused by derepressed ACT-9 was confirmed with anampDknockout mutant of PA1.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference17 articles.
1. Incidence of class A extended-spectrum β-lactamases in Champagne-Ardenne (France): a 1 year prospective study;Brasme;J. Antimicrob. Chemother,2007
2. Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice;Burkhardt;Expert Opin. Pharmacother,2007
3. Contribution of outer membrane protein K36 to antimicrobial resistance and virulence in Klebsiella pneumoniae;Chen;J. Antimicrob. Chemother,2010
4. Performance standards for antimicrobial susceptibility testing; 19th informational supplement;Clinical and Laboratory Standards Institute,2009
5. Performance standards for antimicrobial susceptibility testing; update;Clinical and Laboratory Standards Institute,2010
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献